News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Receives European Marketing Authorization for Lonquex® (XM22 lipegfilgrastim)


8/8/2013 11:18:03 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced today that the European Commission has granted marketing authorization for Lonquex® (lipegfilgrastim). This approval provides the regulatory framework for the commercialization of Lonquex® in all twenty eight countries of the European Union plus Norway, Iceland and Liechtenstein.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES